SPM 927
Lacosamide
CAS: 175481-36-4
Molecular Formula: C13H18N2O3
SPM 927 - Names and Identifiers
| Name | Lacosamide |
| Synonyms | SPM 927 LACOSAMIDE Erlosamide ADD 243037 Lacosamide Harkoseride N~2~-acetyl-N-benzyl-O-methyl-D-serinamide (R)-2-acetamido-N-benzyl-3-methoxypropanamide (R)-2-Acetamido-N-benzyl-3-methoxypropanamide (2R)-2-acetamido-N-benzyl-3-methoxy-propanamide (2R)-2-(Acetylamino)-3-methoxy-N-(phenylmethyl)propanamide |
| CAS | 175481-36-4 |
| EINECS | 605-756-0 |
| InChI | InChI=1/C13H18N2O3/c1-10(16)15-12(9-18-2)13(17)14-8-11-6-4-3-5-7-11/h3-7,12H,8-9H2,1-2H3,(H,14,17)(H,15,16)/t12-/m1/s1 |
| InChIKey | VPPJLAIAVCUEMN-GFCCVEGCSA-N |
SPM 927 - Physico-chemical Properties
| Molecular Formula | C13H18N2O3 |
| Molar Mass | 250.29 |
| Density | 1.120±0.06 g/cm3(Predicted) |
| Melting Point | 141-143?C |
| Boling Point | 536.4±50.0 °C(Predicted) |
| Specific Rotation(α) | D23 +16.0° (c = 1 in CH3OH) |
| Flash Point | 2℃ |
| Vapor Presure | 1.4E-11mmHg at 25°C |
| pKa | 14.19±0.46(Predicted) |
| Storage Condition | Refrigerator |
| Refractive Index | 1.52 |
SPM 927 - Risk and Safety
| Risk Codes | R11 - Highly Flammable R20/21/22 - Harmful by inhalation, in contact with skin and if swallowed. R36 - Irritating to the eyes |
| Safety Description | S16 - Keep away from sources of ignition. S26 - In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. S36/37 - Wear suitable protective clothing and gloves. |
| UN IDs | UN 1648 3 / PGII |
| WGK Germany | 2 |
| HS Code | 2924296000 |
SPM 927 - Reference Information
| Introduction | lacosamide was developed by UCB, first approved for marketing by the European Medicines Agency (EMA) on August 29, 2008and then approved for marketing by the United States Food and Drug Administration (FDA) on October 28, 2008, trade name Vimpat. Lacosamide has a dual mechanism of action. In vitro electrophysiological studies have shown that lacosamide can selectively increase the slow inactivation of voltage-gated sodium channels, stabilize the cell membrane of overexcited neurons, and inhibit repeated firing of neurons. |
| Application | lacosamide is a novel NMDA receptor glycine site binding antagonist, which belongs to a new class of functional amino acids, it is an anticonvulsant drug with a new dual mechanism. It selectively promotes slow inactivation of sodium channels and regulates collapse response-mediating protein -2 (CRMP-2), while CRMP-2 may slow or even prevent seizures and reduce neuropathic pain in diabetes. |
| antiepileptic drug | lacosamide is a new type of antiepileptic drug, which is approved by Belgium EUB (UCB Pharma). A novel N-methyl-D-aspartate (NMDA) receptor glycine site binding antagonist developed by the German subsidiary, Schwarz BioSciences. NMDA receptor glycine site binding antagonist, which belongs to a new class of functional amino acids, is an anticonvulsant drug with a new dual mechanism. It selectively promotes slow inactivation of sodium channels and modulates collapse response-mediating protein 22 (CRMP22), which may slow or even prevent seizures and reduce neuropathic pain in diabetes. Diabetic neuropathic pain affects a large proportion of patients with diabetes, but there is no effective treatment. It is reported that the U. S. Food and Drug Administration has agreed to accept lacosamide for the treatment of diabetic neuropathic pain NDA applications. its mechanism of action is different from that of other antiepileptic drugs. Patients who cannot control symptoms with existing drugs can use this product. UCB's Lacosamide tablets (English name: Lacosamide) were approved by the European Union in September 2008 for the adjuvant treatment of partial seizures in patients aged 16 years and older with or without secondary grand mal. In October 2008, the US FDA approved lacosamide as an adjunct to other drugs for the treatment of partial seizures in patients over 17 years of age under the trade name Vimpat. Vimpat is approved for marketing in 2 dosage forms: Film sheet (50, 100, 150 and 200 mg/tablet), injection (10 mg/mL,20mL/tablet), injectable solutions are suitable for short-term substitution of oral preparations for patients who are not suitable for oral administration. Intellectual property status: patent-free. (Relevant patent No.: 201010183521.7 [UCB Pharmaceutical Co., Ltd.]; 200580024175.5 [schuwaz Pharmaceuticals Co., Ltd.]) |
| Use | antiepileptic drugs |
Last Update：2024-04-09 20:52:54
Supplier List
Spot supply
Product Name: LACOSAMIDE Visit Supplier Webpage Request for quotationCAS: 175481-36-4
Tel: +86 0571-86722205
Email: sales@chinaskyrun.com
Mobile: +8618958170122
QQ: 2531159185
Wechat: chinaskyrun
Spot supply
Product Name: Lacosamide Visit Supplier Webpage Request for quotationCAS: 175481-36-4
Tel: +86-400-900-4166
Email: product@acmec-e.com
Mobile: +86-18621343501
QQ: 2881950922
Wechat: 18621343501
WhatsApp: +86-18621343501
Spot supply
Product Name: LACOSAMIDE Visit Supplier Webpage Request for quotationCAS: 175481-36-4
Tel: +86 0571-86722205
Email: sales@chinaskyrun.com
Mobile: +8618958170122
QQ: 2531159185
Wechat: chinaskyrun
Spot supply
Product Name: Lacosamide Visit Supplier Webpage Request for quotationCAS: 175481-36-4
Tel: +86-400-900-4166
Email: product@acmec-e.com
Mobile: +86-18621343501
QQ: 2881950922
Wechat: 18621343501
WhatsApp: +86-18621343501
View History
SPM 927
吡咯酮
2-呋喃丙烯酸
4-BIPHENYL-4-NITROPHENYL KETONE
Benzeneacetic acid, α-broMo-2-Methoxy-, Methyl ester
SODIUM TETRACHLOROAURATE
2-硝基吡啶-6-羧酸
Ethanol,2-[(2-Nitrophenyl)Amino]-
二氯胺B
AMlodipine IMpurity –D(EP)
吡咯酮
2-呋喃丙烯酸
4-BIPHENYL-4-NITROPHENYL KETONE
Benzeneacetic acid, α-broMo-2-Methoxy-, Methyl ester
SODIUM TETRACHLOROAURATE
2-硝基吡啶-6-羧酸
Ethanol,2-[(2-Nitrophenyl)Amino]-
二氯胺B
AMlodipine IMpurity –D(EP)